Wall Street Journal |
AstraZeneca's Severe Asthma Drug Positive in Phase III
Zacks.com These randomized, double-blind, parallel-group, placebo-controlled studies evaluated the safety and efficacy of benralizumab as an add-on therapy in the treatment of severe uncontrolled asthma with eosinophilic inflammation in patients aged 12 years … AstraZeneca's Asthma Drug Shows Positive Results AstraZeneca set to go head to head against GSK with asthma drug AstraZeneca asthma drug hits goal, to enter competitive market |
View full post on asthma – Google News